Influence of factor XII deficiency on activated partial thromboplastin time (aPTT) in critically ill patients

被引:0
|
作者
Mirjam Bachler
Christian Niederwanger
Tobias Hell
Judith Höfer
Dominic Gerstmeyr
Bettina Schenk
Benedikt Treml
Dietmar Fries
机构
[1] UMIT - University for Health Sciences,Institute for Sports Medicine, Alpine Medicine and Health Tourism
[2] Medical Informatics and Technology,Department of Pediatrics, Pediatric Intensive Care Unit, Pediatrics I
[3] Medical University of Innsbruck,Department of Mathematics, Faculty of Mathematics, Computer Science and Physics
[4] University of Innsbruck,Department of Anesthesiology and Intensive Care Medicine, AUVA Trauma Centre Salzburg
[5] Academic Teaching Hospital of the Paracelsus Medical University,Department of General and Surgical Critical Care Medicine
[6] Medical University Innsbruck,undefined
来源
Journal of Thrombosis and Thrombolysis | 2019年 / 48卷
关键词
Anticoagulation; FXII deficiency; aPTT; Critically ill patients; Thromboprophylaxis;
D O I
暂无
中图分类号
学科分类号
摘要
FXII deficiency results in spontaneous prolongation of activated partial thromboplastin time (aPTT), which is widely used to monitor thromboprophylaxis. Misinterpretation of spontaneously prolonged aPTT may result in omission of thromboembolic treatment or even unnecessary transfusion of blood products. This retrospective analysis was performed to calculate a threshold level of FXII resulting in aPTT prolongation. 79 critically ill patients with spontaneous prolongation of aPTT were included. A correlation analysis and a ROC curve for aPTT prolongation predicted by FXII level were created to find the FXII threshold level. Prolongation of aPTT was associated with disease severity. A significant inverse proportionality between FXII and aPTT was seen. A ROC curve for aPTT prolongation, predicted by FXII level (AUC 0.85; CI 0.76–0.93), revealed a FXII threshold level of 42.5%. Of our patients 50.6% experienced a FXII deficiency, in 80.0% of whom we found aPTT to be prolonged without a significantly higher bleeding rate. The FXII deficiency was more common in patients with higher SAPS3 scores, septic shock, transfusion of red blood cells and platelet concentrates as well as in patients receiving renal replacement therapy. Patients with a FXII deficiency and prolonged aPTT less often received anticoagulatory therapy although they were more severely ill. The rate of thromboembolic events was higher in these patients although the difference was not statistically significant. Of all patients with spontaneous aPTT prolongation 50.6% had a FXII level of 42.5% or less. Those patients received insufficient thromboembolic prophylaxis.
引用
收藏
页码:466 / 474
页数:8
相关论文
共 50 条
  • [31] Role of thromboelastography in the evaluation of septic shock patients with normal prothrombin time and activated partial thromboplastin time
    Kim, Sang-Min
    Kim, Sang-Il
    Yu, Gina
    Kim, June-Sung
    Hong, Seok In
    Chae, Bora
    Shin, Yo Sep
    Kim, Youn-Jung
    Jang, Seongsoo
    Kim, Won Young
    SCIENTIFIC REPORTS, 2021, 11 (01)
  • [32] Prothrombine and activated partial thromboplastin time are prolonged in hepatic cirrhosis
    Limijadi, Edward Kurnia Setiawan
    Suromo, Lisyani Budi
    Budiwiyono, Imam
    UNIVERSA MEDICINA, 2016, 35 (01) : 26 - 32
  • [33] Activated partial thromboplastin time is a better trending tool in pediatric extracorporeal membrane oxygenation
    Maul, Timothy M.
    Wolff, Erin L.
    Kuch, Bradley A.
    Rosendorff, Adam
    Morell, Victor O.
    Wearden, Peter D.
    PEDIATRIC CRITICAL CARE MEDICINE, 2012, 13 (06) : E363 - E371
  • [34] An ex vivo comparison of partial thromboplastin time and activated clotting time for heparin anticoagulation in an ovine model
    Berk, Zachary B. K.
    Shah, Aakash
    Sun, Wenji
    Griffith, Bartley P.
    Wu, Zhongjun J.
    ARTIFICIAL ORGANS, 2022, 46 (03) : 501 - 505
  • [35] Recommendations for Appropriate Activated Partial Thromboplastin Time Reagent Selection and Utilization
    Fritsma, George A.
    Dembitzer, Francine R.
    Randhawa, Ankush
    Marques, Marisa B.
    Van Cott, Elizabeth M.
    Adcock-Funk, Dorothy
    Peerschke, Ellinor I.
    AMERICAN JOURNAL OF CLINICAL PATHOLOGY, 2012, 137 (06) : 904 - 908
  • [36] More on the Limitations of the Activated Partial Thromboplastin Time for Monitoring Argatroban Therapy
    Guy, Susan
    Van Veen, Joost
    Kitchen, Steve
    SEMINARS IN THROMBOSIS AND HEMOSTASIS, 2017, 43 (06) : 642 - 643
  • [37] Comparative analysis on characteristics of two activated partial thromboplastin time reagents
    Yasui, Yutaro
    Ishii, Toshiaki
    Tatebe, Junko
    Morita, Toshisuke
    JOURNAL OF CLINICAL LABORATORY ANALYSIS, 2022, 36 (09)
  • [38] Concordance Between Active Partial Thromboplastin Time and Anti-Factor Xa Assays in Neurocritically Ill Patients Receiving Subcutaneous Heparin Prophylaxis
    Shinn, Grace
    Berger, Karen
    Roh, David
    Doyle, Kevin
    Boehme, Amelia K.
    Connolly, Edward Sander
    Park, Soojin
    Agarwal, Sachin
    Claassen, Jan
    Der-Nigoghossian, Caroline
    NEUROHOSPITALIST, 2023, 13 (03) : 221 - 227
  • [39] Factor XII deficiency and cardiopulmonary bypass: Use of a novel modification of the activated clotting time to monitor anticoagulation
    Gerhardt, MA
    Greenberg, CS
    Slaughter, TF
    Smith, MS
    ANESTHESIOLOGY, 1997, 87 (04) : 990 - 992
  • [40] Use of a modified activated partial thromboplastin time to detect lupus anticoagulants
    Cloherty, T
    Golden, EA
    Lind, SE
    THROMBOSIS RESEARCH, 1996, 83 (02) : 137 - 142